Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI.

Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR Jr, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS.

Hum Brain Mapp. 2010 May;31(5):786-97. doi: 10.1002/hbm.20905. Erratum in: Hum Brain Mapp. 2010 Dec;31(12):2015.

2.

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M; AN1792 (QS-21)-251 Study Team.

Curr Alzheimer Res. 2009 Apr;6(2):144-51.

3.

Visuospatial deficits predict rate of cognitive decline in autopsy-verified dementia with Lewy bodies.

Hamilton JM, Salmon DP, Galasko D, Raman R, Emond J, Hansen LA, Masliah E, Thal LJ.

Neuropsychology. 2008 Nov;22(6):729-37. doi: 10.1037/a0012949.

4.

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.

Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ; Alzheimer Disease Cooperative Study.

JAMA. 2008 Oct 15;300(15):1774-83. doi: 10.1001/jama.300.15.1774.

5.

Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.

van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR Jr, DeCarli C; Alzheimer's Disease Cooperative Study Group.

J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25.

6.

Neurology.

Thal LJ.

West J Med. 1998 Apr;168(4):261. No abstract available.

7.

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ.

Arch Neurol. 2008 Aug;65(8):1031-8. doi: 10.1001/archneur.65.8.1031.

8.

Cognitive discrepancies versus APOE genotype as predictors of cognitive decline in normal-functioning elderly individuals: a longitudinal study.

Fine EM, Delis DC, Wetter SR, Jacobson MW, Jak AJ, McDonald CR, Braga JC, Thal LJ, Salmon DP, Bondi MW.

Am J Geriatr Psychiatry. 2008 May;16(5):366-74. doi: 10.1097/JGP.0b013e3181629957.

9.

Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial.

Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ.

Curr Alzheimer Res. 2008 Feb;5(1):73-82.

PMID:
18288935
10.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264
11.

Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease.

Li Y, Grupe A, Rowland C, Holmans P, Segurado R, Abraham R, Jones L, Catanese J, Ross D, Mayo K, Martinez M, Hollingworth P, Goate A, Cairns NJ, Racette BA, Perlmutter JS, O'Donovan MC, Morris JC, Brayne C, Rubinsztein DC, Lovestone S, Thal LJ, Owen MJ, Williams J.

Hum Mol Genet. 2008 Mar 1;17(5):759-67. Epub 2007 Dec 6.

PMID:
18063669
12.

APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study.

Delano-Wood L, Houston WS, Emond JA, Marchant NL, Salmon DP, Jeste DV, Thal LJ, Bondi MW.

Int J Geriatr Psychiatry. 2008 Jun;23(6):632-6.

13.

Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease.

Mickes L, Wixted JT, Fennema-Notestine C, Galasko D, Bondi MW, Thal LJ, Salmon DP.

Neuropsychology. 2007 Nov;21(6):696-705.

PMID:
17983283
14.

In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution.

Weisman D, Cho M, Taylor C, Adame A, Thal LJ, Hansen LA.

Neurology. 2007 Jul 24;69(4):356-9.

PMID:
17646627
15.

Prevalence of dementia in Chamorros on Guam: relationship to age, gender, education, and APOE.

Galasko D, Salmon D, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Brooks P, Adonay R, Craig UK, Schellenberg G, Borenstein AR.

Neurology. 2007 May 22;68(21):1772-81.

PMID:
17515539
16.

Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam.

Borenstein AR, Mortimer JA, Schofield E, Wu Y, Salmon DP, Gamst A, Olichney J, Thal LJ, Silbert L, Kaye J, Craig UL, Schellenberg GD, Galasko DR.

Neurology. 2007 May 22;68(21):1764-71.

PMID:
17515538
17.

Density of the brain, decline of the mind: an atypical case of Fahr disease.

Weisman DC, Yaari R, Hansen LA, Thal LJ.

Arch Neurol. 2007 May;64(5):756-7. No abstract available.

PMID:
17502478
18.

Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack CR, Jagust W, Trojanowski JQ, Toga AW, Beckett L.

Alzheimers Dement. 2005 Jul;1(1):55-66.

19.

Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.

Jack CR Jr, Petersen RC, Grundman M, Jin S, Gamst A, Ward CP, Sencakova D, Doody RS, Thal LJ; Members of the Alzheimer's Disease Cooperative Study (ADCS).

Neurobiol Aging. 2008 Sep;29(9):1285-95. Epub 2007 Apr 23.

20.

Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms.

Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM.

Mol Neurodegener. 2007 Apr 12;2:7.

21.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study.

Neurology. 2007 May 8;68(19):1588-95. Epub 2007 Feb 7.

PMID:
17287448
22.

Nerve growth factor promotes survival of new neurons in the adult hippocampus.

Frielingsdorf H, Simpson DR, Thal LJ, Pizzo DP.

Neurobiol Dis. 2007 Apr;26(1):47-55. Epub 2006 Dec 20.

PMID:
17270453
23.

Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.

DeCarli C, Frisoni GB, Clark CM, Harvey D, Grundman M, Petersen RC, Thal LJ, Jin S, Jack CR Jr, Scheltens P; Alzheimer's Disease Cooperative Study Group.

Arch Neurol. 2007 Jan;64(1):108-15. Erratum in: Arch Neurol. 2007 Mar;64(3):459.

PMID:
17210817
24.

Disparate letter and semantic category fluency deficits in autopsy-confirmed frontotemporal dementia and Alzheimer's disease.

Rascovsky K, Salmon DP, Hansen LA, Thal LJ, Galasko D.

Neuropsychology. 2007 Jan;21(1):20-30.

PMID:
17201527
25.

ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.

Sano M, Zhu CW, Whitehouse PJ, Edland S, Jin S, Ernstrom K, Thomas RG, Thal LJ, Ferris SH; Alzheimer Disease Cooperative Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S191-202.

26.

ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials.

Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini E, Petersen RC, Edland SD, Thal LJ, Ferris SH; Alzheimer's Disease Cooperative Study.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S139-46.

PMID:
17135807
27.

ADCS Prevention Instrument Project: overview and initial results.

Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ; Alzheimer's Disease Cooperative Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S109-23.

PMID:
17135805
28.

Spanish instrument protocol: new treatment efficacy instruments for Spanish-speaking patients in Alzheimer disease clinical trials.

Sano M, Egelko S, Jin S, Cummings J, Clark CM, Pawluczyk S, Thomas RJ, Schittini M, Thal LJ; Alzheimer's Disease Cooperative Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):232-41.

29.

Common threads in neurodegenerative disorders of aging.

Beal MF, Bossy-Wetzel E, Finkbeiner S, Fiskum G, Giasson B, Johnson C, Khachaturian ZS, Lee VM, Nicholls D, Reddy H, Reynolds I, Teplow DB, Thal LJ, Trojanowski JQ, Walsh DM, Wetzel R, Wexler NS, Young AB, Bain L.

Alzheimers Dement. 2006 Oct;2(4):322-6. doi: 10.1016/j.jalz.2006.08.008. No abstract available.

30.

Prevention of Alzheimer disease.

Thal LJ.

Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3 Suppl 2):S97-9. Review.

PMID:
16917204
31.

Robert Katzman honored.

Thal LJ, Kawas C, Galasko D, Salmon DP, Sundsmo MP.

Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3 Suppl 2):S27-8. No abstract available.

PMID:
16917190
32.

Toward optimal health: Leon J. Thal, M.D. discusses the latest in Alzheimer's disease in women. Interview by Jodi R. Godfrey.

Thal LJ.

J Womens Health (Larchmt). 2006 Jul-Aug;15(6):704-8. No abstract available.

PMID:
16910902
33.

DAPK1 variants are associated with Alzheimer's disease and allele-specific expression.

Li Y, Grupe A, Rowland C, Nowotny P, Kauwe JS, Smemo S, Hinrichs A, Tacey K, Toombs TA, Kwok S, Catanese J, White TJ, Maxwell TJ, Hollingworth P, Abraham R, Rubinsztein DC, Brayne C, Wavrant-De Vrièze F, Hardy J, O'Donovan M, Lovestone S, Morris JC, Thal LJ, Owen M, Williams J, Goate A.

Hum Mol Genet. 2006 Sep 1;15(17):2560-8. Epub 2006 Jul 17.

PMID:
16847012
34.

Alzheimer's Association Research Roundtable Meeting on Mild Cognitive Impairment: what have we learned?

Grundman M, Petersen RC, Bennett DA, Feldman HH, Salloway S, Visser PJ, Thal LJ, Schenk D, Khachaturian Z, Thies W; Alzheimer's Association Research Roundtable.

Alzheimers Dement. 2006 Jul;2(3):220-33. doi: 10.1016/j.jalz.2006.04.010.

PMID:
19595891
35.

Retraction.

Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, Parker WD.

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):12069. No abstract available.

36.

Utility of the telephone interview for cognitive status for enrollment in clinical trials.

Yaari R, Fleisher AS, Gamst AC, Bagwell VP, Thal LJ.

Alzheimers Dement. 2006 Apr;2(2):104-9. doi: 10.1016/j.jalz.2006.02.004.

PMID:
19595866
37.

The role of biomarkers in clinical trials for Alzheimer disease.

Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Praticò D, Griffin S, Schenk D, Siemers E.

Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15. Review.

38.

The Alzheimer's disease neuroimaging initiative.

Mueller SG, Weiner MW, Thal LJ, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Toga AW, Beckett L.

Neuroimaging Clin N Am. 2005 Nov;15(4):869-77, xi-xii. Review.

39.

Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response.

Han SD, Houston WS, Jak AJ, Eyler LT, Nagel BJ, Fleisher AS, Brown GG, Corey-Bloom J, Salmon DP, Thal LJ, Bondi MW.

Neurobiol Aging. 2007 Feb;28(2):238-47. Epub 2006 Jan 24.

40.

What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?

Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J.

Brain. 2006 Mar;129(Pt 3):729-35. Epub 2006 Jan 9.

PMID:
16401618
41.

Identification of Alzheimer disease risk by functional magnetic resonance imaging.

Fleisher AS, Houston WS, Eyler LT, Frye S, Jenkins C, Thal LJ, Bondi MW.

Arch Neurol. 2005 Dec;62(12):1881-8.

PMID:
16344346
42.

The septohippocampal cholinergic system and spatial working memory in the Morris water maze.

Frielingsdorf H, Thal LJ, Pizzo DP.

Behav Brain Res. 2006 Mar 15;168(1):37-46. Epub 2005 Dec 5.

PMID:
16330106
43.

Regulatable acetylcholine-producing fibroblasts enhance cognitive performance.

Pizzo DP, Coufal NG, Lortie MJ, Gage FH, Thal LJ.

Mol Ther. 2006 Jan;13(1):175-82. Epub 2005 Sep 26.

44.

Anosmia is very common in the Lewy body variant of Alzheimer's disease.

Olichney JM, Murphy C, Hofstetter CR, Foster K, Hansen LA, Thal LJ, Katzman R.

J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1342-7.

45.

Reminiscences: Robert Katzman and Robert Terry.

Thal LJ.

Alzheimers Dement. 2005 Jul;1(1):73. doi: 10.1016/j.jalz.2005.06.009. No abstract available.

PMID:
19595821
46.

Regression to the mean: implications for clinical trials of psychotropic agents in dementia.

Cummings JL, Tractenberg RE, Gamst A, Teri L, Masterman D, Thal LJ.

Curr Alzheimer Res. 2004 Nov;1(4):323-8.

47.

Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment.

Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study.

Arch Neurol. 2005 Jun;62(6):953-7.

PMID:
15956166
48.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group.

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

49.

Smoking affects the phenotype of Alzheimer disease.

Sabbagh MN, Tyas SL, Emery SC, Hansen LA, Alford MF, Reid RT, Tiraboschi P, Thal LJ.

Neurology. 2005 Apr 12;64(7):1301-3.

PMID:
15824373
50.

Growth factor gene therapy for Alzheimer disease.

Tuszynski MH, U HS, Alksne J, Bakay RA, Pay MM, Merrill D, Thal LJ.

Neurosurg Focus. 2002 Nov 15;13(5):e5. Review.

PMID:
15769074

Supplemental Content

Support Center